-

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences:

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Share

A.G.P. Virtual Consumer Showcase

  • Virtual showcase offering consumer company management teams a platform to share their story with the investment community
  • Location: Virtual
  • Date: November 11 - 12, 2026
  • Format: Fireside chat Thursday, November 12, 2026 at 3:00 p.m. ET
  • Management: Rob Fried, CEO & Ozan Pamir, CFO
  • Investors may register here

Southwest IDEAS Investor Conference

  • Independent institutional investor conference for publicly traded companies and institutional investors
  • Location: The Westin Irving Convention Center in Las Colinas, Irving, Texas
  • Date: November 18 - 19, 2026
  • Format: Presentation on Thursday, November 19, 2026 from 4:00 - 4:35 p.m. CT and one-on-one meetings
  • Management: Rob Fried, CEO & Ozan Pamir, CFO

15th Annual ROTH Deer Valley Event

  • Invite-only annual networking conference for institutional investors and select public/private company management teams.
  • Location: Montage Deer Valley Park City, Utah
  • Date: December 9 - 12, 2026
  • Format: One-on-one meetings
  • Management: Rob Fried, CEO

StoneX 15th Annual Discovery Conference 2026

  • Emerging growth investor forum for institutional investors and select public and private emerging growth companies.
  • Location: New York Athletic Club New York, New York
  • Date: December 10, 2026
  • Format: One-on-one meetings
  • Management: Ozan Pamir, CFO

If you would like to schedule a one-on-one meeting with the Niagen management team during either conference, please contact your respective conference representative or email Niagen@KCSA.com.

For additional information on Niagen Bioscience, visit www.niagenbioscience.com.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically tested product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

†Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

Contacts

Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Niagen@kcsa.com

Niagen Bioscience, Inc

NASDAQ:NAGE

Release Versions
$Cashtags

Contacts

Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Niagen@kcsa.com

Social Media Profiles
More News From Niagen Bioscience, Inc

Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it will support the Sixth Annual Longevity Summit taking place from December 9 to 10, 2026, at the Buck Institute for Research on Aging in Novato, California. The Summit, themed “The Future of Medicine: Eliminating Diseases of Aging,” convenes researchers, investors and government organizations to dis...

Niagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ Plus 

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has partnered with Truemed to provide qualified customers the option to purchase the Niagen™ At-Home Injection Kit using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds, now available through its Niagen™ Plus telehealth platform. Qualified customers may use HSA/FSA funds...

Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026. Third Quarter 2026 Financial and Business Highlights Total net sales of $27.2 million, including $23.3 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 13% year-over-year. Gross margin of 62....
Back to Newsroom